NOVO NORDISK A/S |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1,003 DKK | -0.44% |
|
+0.89% | +43.62% |
ETFs positioned on Novo Nordisk A/S
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.56% | 607 M€ | +0.05% | - | |
| 0.47% | 205 M€ | -.--% | ||
| 0.43% | 251 M€ | +8.13% | ||
| 0.39% | 288 M€ | +26.38% | ||
| 0.29% | 414 M€ | +11.85% | - | |
| 0.26% | 0 M€ | 0.00% | - | |
| 0.24% | 36 M€ | +10.56% | - | |
| 0.18% | 324 M€ | +8.20% | - | |
| 0.18% | 40 M€ | +6.72% | - | |
| 0.17% | 20 M€ | +1.13% | - | |
| 0.15% | 104 M€ | +5.45% | - | |
| 0.13% | 32 M€ | +4.54% | - | |
| 0.12% | 17 M€ | +3.32% | - | |
| 0.09% | 248 M€ | +16.04% | - | |
| 0.07% | 55 M€ | +2.00% | - |
Novo Nordisk A/S specializes in the design, manufacture and marketing of pharmaceutical products. Net sales break down by family of products as follows:
- diabetes and obesity treatment products (92.6%);
- rare disease treatment products (7.4%): intended for the treatment of haemophilia, blood disorders, hormonal disorders, etc.
Net sales are distributed geographically as follows: Europe/Middle East/Africa (21.9%), the United States (54.9%), North America (3.9%), China (7.2%) and other (12.1%).
Sector
Pharmaceuticals
Calendar
2024-08-07
- Q2 2024 Earnings Release
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
B
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
26
Last Close Price
1,007
DKK
Average target price
937.9
DKK
Spread / Average Target
-6.86%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +43.62% | 640B | |
| +55.10% | 811B | |
| -7.12% | 353B | |
| +17.91% | 333B | |
| +8.90% | 302B | |
| +16.30% | 246B | |
| +2.41% | 225B | |
| +12.47% | 218B | |
| +8.57% | 168B | |
| -3.58% | 155B |
- Stock Market
- Equities
- NOVO B Stock
- Funds and ETFs Novo Nordisk A/S
